v3.26.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Revenues    
Service $ 58,949 $ 115,476
Product 926,127 130,909
Total Revenues 985,076 246,385
Operating Expenses    
Research and development 2,852,251 2,607,444
General and administrative 2,629,826 2,243,362
Sales and marketing 851,851 917,299
Total Operating Expenses 6,333,928 5,768,105
Operating Loss (5,348,852) (5,521,720)
Other Income (Expense)    
Grant income 120,531 121,566
Interest income 16 158
Interest expense (125,842) (96,669)
Amortization of debt discount (450,134) 0
Gain on change in fair value of warrant liability 13,416 20,038
Gain on change in fair value of derivative liability 98,642 0
Loss on extinguishment of debt (1,011,334) 0
Total Other Income (Expenses) (1,354,705) 45,093
Net Loss (6,703,557) (5,476,627)
Net Loss Attributable to Non-Controlling Interest 38,783 52,868
Net Loss Attributable to VolitionRx Stockholders (6,664,774) (5,423,759)
Other Comprehensive Income (Loss)    
Foreign currency translation adjustments 134,307 (253,929)
Net Comprehensive Loss $ (6,569,250) $ (5,730,556)
Loss Per Common Share - Attributable to Common Stockholders - Basic and Diluted $ (0.97) $ (1.12)
Weighted Average Shares Outstanding - Basic and Diluted 6,882,744 4,826,803

Source

10-Q PDF
XBRL